Hansen JC, Deguchi Y
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P
First, it allows the gastrointestinal system to adapt to cagrilintide's effects on gastric emptying, significantly reducing nausea and vomiting incidents
Clinical studies suggest these peptides are generally well-tolerated within tested dose ranges, with minimal side effects
An ACQUITY UPLC system (Waters, Milford, MA, United States) interfaced with a triple quadrupole mass spectrometer (TQS) that is equipped with an ESI source was employed for UPLC-MS/MS analyses (Wang et al., 2021)